STBT5:Angiomyofibroblastoma: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 125: | Line 125: | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
# '''Fusion testing''' | #'''Fusion testing''' | ||
#* Targeted sequencing (such as RT-PCR or targeted next-generation sequencing (NGS) panels) | #*Targeted sequencing (such as RT-PCR or targeted next-generation sequencing (NGS) panels) | ||
#** For targeted NGS panels, consider if the assay requires both gene partners to be included on the panel or if it is able to identify novel fusions as long as one of the partners is included on the panel | #**For targeted NGS panels, consider if the assay requires both gene partners to be included on the panel or if it is able to identify novel fusions as long as one of the partners is included on the panel | ||
#* Whole transcriptome RNA-sequencing | #*Whole transcriptome RNA-sequencing | ||
#** Provides an unbiased approach to fusion calling | #**Provides an unbiased approach to fusion calling | ||
==Familial Forms== | ==Familial Forms== | ||
| Line 138: | Line 138: | ||
None | None | ||
==References== | ==References== | ||
<br /> | <references /><br /> | ||
==Notes== | ==Notes== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. | ||
| Line 147: | Line 147: | ||
[[Category:DISEASE]] | [[Category:DISEASE]] | ||
[[Category:Diseases A]] | [[Category:Diseases A]] | ||
<references /> | |||